TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cross-Over Comparative Study of Inhaled Mannitol, Alone and in Combination With Daily rhDNase, in Children With Cystic Fibrosis
Brief Summary: The purpose of this study is to determine the medium term efficacy and safety profile of inhaled mannitol, on its own and also as an additional therapy to rhDNase (pulmozyme). In particular, we will assess the impact on: lung function; airway inflammation; sputum microbiology; exacerbations; quality of life; adverse events; exercise tolerance; total costs of hospital and community care; and cost-effectiveness.


Options:
A: Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mannitol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dornase alpha | Arm Label: 3; Type: OTHER; Interventions: Drug: mannitol + pulmozyme | Intervention Type: DRUG; Name: mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: mannitol + pulmozyme; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dornase alpha; Assigned to Arm(s): 2
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cross-Over Comparative Study of Inhaled Mannitol, Alone and in Combination With Daily rhDNase, in Children With Cystic Fibrosis
Brief Summary: The purpose of this study is to determine the medium term efficacy and safety profile of inhaled mannitol, on its own and also as an additional therapy to rhDNase (pulmozyme). In particular, we will assess the impact on: lung function; airway inflammation; sputum microbiology; exacerbations; quality of life; adverse events; exercise tolerance; total costs of hospital and community care; and cost-effectiveness.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypertonic saline 6% - | Intervention Type: DRUG; Name: Hypertonic saline 6% -; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: OTHER; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mannitol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dornase alpha | Arm Label: 3; Type: OTHER; Interventions: Drug: mannitol + pulmozyme | Intervention Type: DRUG; Name: mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: mannitol + pulmozyme; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dornase alpha; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Pediatric Patients (Ages 6 to 14 Years) With Acute Asthma
Brief Summary: This study will attempt to find out if the addition of an intravenous form of a drug that is already used for treating asthma in children will help resolve asthma attacks faster than using the current standard care alone.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: rhDNAse (pulmozyme); Assigned to Arm(s): N/A
C: Arm Label: salbutamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: salbutamol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: salbutamol; Assigned to Arm(s): salbutamol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Montelukast 7 mg; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): Montelukast 7 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Pediatric Patients (Ages 6 to 14 Years) With Acute Asthma
Brief Summary: This study will attempt to find out if the addition of an intravenous form of a drug that is already used for treating asthma in children will help resolve asthma attacks faster than using the current standard care alone.


Options:
A: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A
B: Arm Label: Montelukast 7 mg; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): Montelukast 7 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 1
D: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's Disease
Brief Summary: The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Vitamin C, and Alpha-lipoic Acid, Drug: Placebo wafers | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Coenzyme Q, Drug: Placebo capsules | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules, Drug: Placebo wafers | Intervention Type: DRUG; Name: Vitamin E, Vitamin C, and Alpha-lipoic Acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Coenzyme Q; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo wafers; Assigned to Arm(s): 1, 3
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol, Drug: Memantine | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4
C: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
D: Arm Label: MRI(+ve),; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 200mg of Palm vitamin E (tocotrienols) or placebo | Arm Label: MRI(-ve); Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 200mg of Palm vitamin E (tocotrienols) or placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 200mg of Palm vitamin E (tocotrienols) or placebo; Assigned to Arm(s): MRI(+ve),, MRI(-ve)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's Disease
Brief Summary: The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol, Drug: Memantine | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4
B: Arm Label: Ginkgo Synergy® and Choline; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ginkgo Synergy® and Choline | Arm Label: OPC Synergy® and Catalyn; Type: EXPERIMENTAL; Interventions: Dietary Supplement: OPC Synergy® and Catalyn | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Ginkgo Synergy® and Choline; Assigned to Arm(s): Ginkgo Synergy® and Choline | Intervention Type: DIETARY_SUPPLEMENT; Name: OPC Synergy® and Catalyn; Assigned to Arm(s): OPC Synergy® and Catalyn | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Nutriceutical formulation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutriceutical formulation | Arm Label: Placebo 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutriceutical formulation; Assigned to Arm(s): Nutriceutical formulation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 1, Placebo 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Vitamin C, and Alpha-lipoic Acid, Drug: Placebo wafers | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Coenzyme Q, Drug: Placebo capsules | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules, Drug: Placebo wafers | Intervention Type: DRUG; Name: Vitamin E, Vitamin C, and Alpha-lipoic Acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Coenzyme Q; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo wafers; Assigned to Arm(s): 1, 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Anti-IgE Antibody Omalizumab (Xolair) on Patients With Chronic Sinusitis and a Positive Allergen Test
Brief Summary: The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-IgE antibody omalizumab or placebo | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Anti-IgE antibody omalizumab or placebo | Intervention Type: DRUG; Name: Anti-IgE antibody omalizumab or placebo; Assigned to Arm(s): 1, 2
B: Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab SAR231893 (REGN668), Drug: Mometasone furoate nasal spray | Arm Label: Dupilumab 300 mg q2w then q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab SAR231893 (REGN668), Drug: Placebo, Drug: Mometasone furoate nasal spray | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Mometasone furoate nasal spray | Intervention Type: DRUG; Name: Dupilumab SAR231893 (REGN668); Assigned to Arm(s): Dupilumab 300 mg q2w, Dupilumab 300 mg q2w then q4w | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Dupilumab 300 mg q2w then q4w, Placebo | Intervention Type: DRUG; Name: Mometasone furoate nasal spray; Assigned to Arm(s): Dupilumab 300 mg q2w, Dupilumab 300 mg q2w then q4w, Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for dupilumab), Drug: Mometasone furoate nasal spray | Arm Label: Dupilumab 300 mg QW; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Mometasone furoate nasal spray | Intervention Type: DRUG; Name: Placebo (for dupilumab); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg QW | Intervention Type: DRUG; Name: Mometasone furoate nasal spray; Assigned to Arm(s): Dupilumab 300 mg QW, Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Open-label, Multi-centre Phase II Study of BAY43-9006 (Sorafenib) Versus Standard Treatment With Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.
Brief Summary: The purpose of the study is to:

* Find out if patients receiving BAY43-9006 will live longer without tumor progression than those receiving standard therapy with interferon alpha-2a
* Find out if a higher dose of BAY43-9006 can inhibit tumor progression in patients who progressed during standard dose treatment with BAY43-9006, and for how long these patients live without progression
* Find out how long patients live without progression who receive BAY43-9006 after failing to respond to standard therapy with interferon alpha-2a
* Find out in how many percent of patients BAY43-9006 prevents the growth of or shrinks kidney tumors and/or their metastases depending on treatment and dosage
* Find out if BAY43-9006 has any effect on the quality of life of patients with kidney cancer
* Find out the level of BAY43-9006 in the blood once per month and any changes in this level
* Find out whether BAY43-9006 effects are associated with specific biomarkers


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib, Drug: AMG 386 placebo IV | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: AMG 386 placebo IV | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 placebo IV; Assigned to Arm(s): Arm A, Arm C
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
C: Arm Label: First Sorafenib (Nexavar, BAY43-9006) 400 mg then 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Arm Label: First Interferon then Sorafenib (Nexavar, BAY43-9006) 400 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): First Sorafenib (Nexavar, BAY43-9006) 400 mg then 600 mg | Intervention Type: DRUG; Name: Interferon; Assigned to Arm(s): First Interferon then Sorafenib (Nexavar, BAY43-9006) 400 mg
D: Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tarceva (erlotinib HCl); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-Selection Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 in Patients With Intermittent Claudication
Brief Summary: The purpose of this Phase 2 clinical research study is to examine the safety of an experimental gene transfer agent, Ad2/HIF-1α/VP16, and its ability to stimulate the growth of new blood vessels from existing blood vessels (a process called angiogenesis) in an attempt to improve the flow of blood in the legs of patients with peripheral arterial disease (PAD).

Specifically, this study will enroll patients with severe intermittent claudication (IC) which is the stage of PAD in which a patient's walking ability is severely limited, causing pain in the legs upon exercise due to inadequate blood flow to the muscles of the lower limbs.


Options:
A: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
B: Arm Label: MESENDO; Type: EXPERIMENTAL; Interventions: Biological: MESENDO | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MESENDO; Assigned to Arm(s): MESENDO | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: NV1FGF 16 mg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 32 mg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): NV1FGF 16 mg, NV1FGF 32 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: Middle Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline (Placebo Control) | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): Low Dose | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): Middle Dose | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): High Dose | Intervention Type: OTHER; Name: Saline (Placebo Control); Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-Selection Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 in Patients With Intermittent Claudication
Brief Summary: The purpose of this Phase 2 clinical research study is to examine the safety of an experimental gene transfer agent, Ad2/HIF-1α/VP16, and its ability to stimulate the growth of new blood vessels from existing blood vessels (a process called angiogenesis) in an attempt to improve the flow of blood in the legs of patients with peripheral arterial disease (PAD).

Specifically, this study will enroll patients with severe intermittent claudication (IC) which is the stage of PAD in which a patient's walking ability is severely limited, causing pain in the legs upon exercise due to inadequate blood flow to the muscles of the lower limbs.


Options:
A: Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: NV1FGF 16 mg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 32 mg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): NV1FGF 16 mg, NV1FGF 32 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Riferminogene pecaplasmid; Type: EXPERIMENTAL; Interventions: Biological: riferminogene pecaplasmid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (for riferminogene pecaplasmid) | Intervention Type: BIOLOGICAL; Name: riferminogene pecaplasmid; Assigned to Arm(s): Riferminogene pecaplasmid | Intervention Type: BIOLOGICAL; Name: Placebo (for riferminogene pecaplasmid); Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
D: Arm Label: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: Middle Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline (Placebo Control) | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): Low Dose | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): Middle Dose | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): High Dose | Intervention Type: OTHER; Name: Saline (Placebo Control); Assigned to Arm(s): Placebo

Answer: D